AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03046628 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TcPO2
Study NCT02946528 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: urgent-start peritoneal dialysis catheter
Description: Patients initiated peritoneal dialysis as urgent-start dialysis modality with a peritoneal dialysis catheter.
Study NCT02946528 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: central venous catheter
Description: Patients initiated hemodialysis as urgent-start dialysis modality with a central venous catheter.
Study NCT01041833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atRA
Description: atRA group will receive six cycles of 80 mg/m2 of cisplatin and 175 mg/m2 of paclitaxel plus atRA 45 m2/day before one week before treatment and during all the treatment
Study NCT02499224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YYB101
Description: Dose-escalation cohort: YYB101 of each dose level (0.3mg/kg to 5mg/kg), IV infusion on Day 1, Day 29, and followed by every 2 weeks until disease progression or unacceptable toxicity development.~Dose-expansion cohort: YYB101 of MTD (or RP2D), IV infusion every 2 weeks until disease progression or unacceptable toxicity development
Study NCT01041833 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo group will receive six cycles of 80 mg/m2 of cisplatin and 175 mg/m2 of paclitaxel plus placebo before one week before treatment and during all the treatment
Study NCT03907228 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: RHT-3201
Description: PROBIOTIC
Study NCT03907228 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: RHT-3201
Description: PROBIOTIC
Study NCT03454542 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Menicon Modified Lens Design
Description: Randomized in a daily wear, single day (6 hours or more) evaluation
Study NCT02921503 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mobile topical corticosteroid app
Description: app used on mobile phones that takes the input of providers and suggests topical corticosteroids with specific information on the ingredient, vehicle, and amount
Study NCT02682186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine after dilution with sodium chloride 0.9%
Description: After the anesthesic induction, the interventional team composed by at least a senior anaesthesiologist and a nurse anesthestic, will survey the patient and perform the Pecs blocks, whereas the anesthetic team is outside the room.~Realization of Pecs blocks 1 and 2 : the patient is in supine position with placing the upper limb in abduction position, a 100 mm needle is inserted under ultrasound using a linear US probe of high frequency after sheathing.~In the other group, sterilization, sheating and US are performed but the needle is not inserted.
Study NCT01258088 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AN2728 Ointment
Description: 5mg/cm2, BID
Study NCT01258088 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AN2728 Vehicle
Description: 5mg/cm2 BID
Study NCT03786419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Participants will be given 1200 mg of Atezolizumab as single agent by IV infusion every 21 days. First infusion will be over 60 min. Subsequent Atezolizumab cycles may be administered for 30 minutes, if there were no perfusion-related toxicity
Study NCT01998386 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gel without hydrogen peroxide
Description: Castings will be made of the upper and lower arches of the volunteers and plaster will be poured into the molds. Individual plastic molds (vacuum form, flexible acetate 1 mm in thickness) will be made for each arch using the plaster models. After fitting the molds in the oral cavity, the volunteers will receive oral and written instructions on how to use the whitening gel and will be instructed to perform proper oral hygiene with dental floss and a tooth brush prior to the application of the whitening agent. The volunteers will be instructed to use the molds with the gel one hour a day for seven days. Thirty days after the beginning of treatment, the volunteers in this group will receive the whitening treatment with 6.0% hydrogen peroxide - White Class with calcium.
Study NCT01998386 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 6.0% hydrogen peroxide - White Class
Description: Castings will be made of the upper and lower arches of the volunteers and plaster will be poured into the molds. Individual plastic molds (vacuum form, flexible acetate 1 mm in thickness) will be made for each arch using the plaster models. After fitting the molds in the oral cavity, the volunteers will receive oral and written instructions on how to use the whitening gel 6.0% hydrogen peroxide - White Class with calcium and will be instructed to perform proper oral hygiene with dental floss and a tooth brush prior to the application of the whitening agent. The volunteers will be instructed to use the molds with whitening gel one hour a day for seven days.
Study NCT01998386 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 7.5% hydrogen peroxide - White Class
Description: Castings will be made of the upper and lower arches of the volunteers and plaster will be poured into the molds. Individual plastic molds (vacuum form, flexible acetate 1 mm in thickness) will be made for each arch using the plaster models. After fitting the molds in the oral cavity, the volunteers will receive oral and written instructions on how to use the whitening gel 7.5% hydrogen peroxide - White Class with calciumand will be instructed to perform proper oral hygiene with dental floss and a tooth brush prior to the application of the whitening agent. The volunteers will be instructed to use the molds with whitening gel one hour a day for seven days.
Study NCT01998386 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 7.5% hydrogen peroxide - Oral-B 3D White
Description: The participants in this group will receive four disposable whitening 7.5% hydrogen peroxide - Oral-B 3D White strips for daily individual use. The volunteers will be instructed to perform proper oral hygiene with dental floss and a tooth brush prior to the application of the whitening strips. The volunteers will receive oral and written instructions on how to use the whitening strips, which will be placed on the surface of the teeth for 30 minutes twice a day for seven days.
Study NCT01363141 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Regular AGE Diet
Description: Regular AGE Diet
Study NCT01363141 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low AGE Diet
Description: One year reduction in dietary AGE intake.
Study NCT04365179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nerofe
Description: Up to 12 cycles of 28 days are planned. If patients are deriving benefit, treatment may continue past 12 cycles.~Cycle 1: During Cycle 1, assigned NEROFE doses will be administered by intravenous (IV) infusion over 1 hour on Days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24 and 26.~Cycles 2-12: Subsequent cycles will be administered as above, presuming that patients do not meet criteria for study withdrawal during cycle 1.
Study NCT02974491 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fuji apple juice
Description: On two different days, each volunteer consumed 300 mL Fuji apple juice (AJ), immediately after a dialysis section. After a washout period of 3 weeks, the volunteers drank 150 mL Fuji AJ in a similar manner as described above. Before and after 30 and 60 min of AJ consumption, blood samples were withdrawn for biochemical analysis.
Study NCT03637335 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: irradiation + carboplatin
Description: 30 Gy en 10 fractions de 3 Gy + 10 injections of carboplatin
Study NCT03637335 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: irradiation + placebo
Description: 30 Gy en 10 fractions de 3 Gy + 10 injections of placebo
Study NCT00452608 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: amido pill
Description: one pill of amido/d by mouth for 10 days
Study NCT00452608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atorvastatina
Description: atorvastatina 80 mg/day by mouth for 10 days
Study NCT04144426 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Normal diet
Description: Participants will receive either a 2000 calorie or a 2500 calorie diet at normal meal times
Study NCT04144426 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified diet
Description: Participants will receive either a 2000 calorie or a 2500 calorie diet with a single meal shift, breakfast is moved to an hour before bedtime.
Study NCT00977223 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: aprepitant/placebo
Description: Aprepitant, 125 MG at day 1 then 80 MG day 2-7, once a day, per os, at 8 AM during breakfast
Study NCT01839981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6,8-bis(benzylthio)octanoic acid
Description: Given IV
Study NCT02636010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Study NCT00135083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin glulisine
Description: * Once Daily Insulin: Subjects will receive insulin glulisine administered once daily 0-15 minutes before the greatest glycemic impact meal of the day starting at one-tenth the total dose of insulin glargine with maximum starting dose of 10 Units, and with additional monitoring as shown in the table below.~* Twice Daily: Subjects will receive insulin glulisine administered twice daily 0-15 minutes before the 2 greatest glycemic impact meals of the day starting at one-tenth the total dose of insulin glargine with a maximum starting dose of 10 Units, and with additional monitoring as shown in the table below.~* Three Times Daily: Subjects will receive insulin glulisine administered 3 times daily 0-15 minutes before each meal of the day starting at one-tenth the total dose of insulin glargine with a maximum starting dose of 10 Units for each meal and additional monitoring as shown in the table below.
Study NCT01908010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-354
Description: ABT-354 Low Dose
Study NCT01908010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-354
Description: ABT-354 High Dose
Study NCT01908010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study NCT02081586 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT
Description: Therapists will work with patients to identify non-constructive thinking patterns that are serving as barriers to adequate self-management of Type 2 Diabetes.
Study NCT02081586 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smartphone app
Description: Smartphone app developed to assist patients practice CBT skills throughout the week
Study NCT02081586 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Diabetes Care at PCP
Description: Patients receive ADA standard of Care with physician at PCP office
Study NCT02081586 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Diabetes Care at PCP
Description: Patients receive ADA standard of Care with physician at PCP office
Study NCT02460276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Study NCT02460276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Study NCT02460276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Study NCT04146155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide+standard-of-care treatment
Description: Liraglutide is available if pre-filled pens (6 mg/ml) as a solution for injection (Victoza®). One ml of solution contains 6 mg of Liraglutide (human glucagon-like peptide-1 analogue produced by recombinant DNA technology in Saccharomyces cerevisiae). One pre-filled pen contains 18 mg Liraglutide in 3 ml.~Liraglutide is added to existing standard-of-care treatment containing one or more oral anti-hyperglycemic agents or insulin or a combination of these agents with the exception of other incretin and SGLT2i therapies in accordance with local clinical practice guidelines.
Study NCT00636064 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Parecoxib Sodium/Valdecoxib
Description: Parecoxib sodium 40 mg intravenous (IV) on the day after surgery (Day 1) following recovery from anesthesia, contingent on an acceptable postoperative status, verification of baseline eligibility, and lack of perioperative complications. A second dose of parecoxib sodium 20 mg IV was administered on Day 1. On the day following surgery, patients received parecoxib 20 mg IV at 8 am and each subsequent dose was administered at 12-hour intervals. After receiving at least 6 doses of IV parecoxib sodium, patients were transitioned to oral valdecoxib 20 mg taken at 12-hour intervals until the total treatment duration of 10 days had been completed.
Study NCT00636064 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo/Valdecoxib
Description: Patients received placebo matched to parecoxib sodium 40 mg IV on Day 1 following recovery from anesthesia, contingent on an acceptable postoperative status, verification of baseline eligibility, and lack of perioperative complications. A second dose of placebo matched to parecoxib sodium 20 mg IV was administered on Day 1. On the day following surgery, patients received placebo matched to parecoxib sodium 20 mg IV at 8 am and each subsequent dose was administered at 12-hour intervals. After receiving at least 6 doses of IV placebo, patients were transitioned to oral valdecoxib 20 mg taken at 12-hour intervals until the total treatment duration of 10 days had been completed.
Study NCT00636064 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo/Placebo
Description: Patients received placebo matched to parecoxib sodium 40 mg IV on Day 1 following recovery from anesthesia, contingent on an acceptable postoperative status, verification of baseline eligibility, and lack of perioperative complications. A second dose of placebo matched to parecoxib sodium 20 mg IV was administered on Day 1. On the day following surgery, patients received placebo matched to parecoxib sodium 20 mg IV at 8 am and each subsequent dose was administered at 12-hour intervals. After receiving at least 6 doses of IV placebo, patients were transitioned to oral placebo matched to valdecoxib 20 mg taken at 12-hour intervals until the total treatment duration of 10 days had been completed.
Study NCT03399370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inclisiran Sodium
Description: Inclisiran is a small interfering ribonucleic acid (RNA) that inhibits PCSK9 synthesis.
Study NCT03399370 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be supplied as sterile normal saline (0.9% sodium chloride in water for injection).
Study NCT04088032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib, durvalumab and aromatase inhibitor
Description: Subjects will receive standard therapy with an aromatase inhibitor (exemestane, anastrozole, or letrozole), combined with the experimental treatment of abemaciclib and durvalumab
Study NCT03691922 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector Spinae Plane (ESP) Block
Description: 1. Preoperative US guided ESP blockade using 30 mL of 0.25% bupivacaine with 5 mcg/mL of epinephrine, injected in 5-mL aliquots through the needle (maximum of 3 mg/kg)~2. PAI of 30 mL of saline at the end of the surgical procedure on the operated side rotator cuff, injected in 5-mL aliquots through the needle
Study NCT03691922 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Periarticular Infiltration (PAI)
Description: 1. Preoperative US guided ESP blockade using 30 mL of saline, injected in 5-mL aliquots through the needle~2. PAI of 30 mL of 0.25% bupivacaine with 5 mcg/mL of epinephrine at the end of the surgical procedure on the operated side rotator cuff, injected in 5-mL aliquots through the needle
Study NCT03508310 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Taking Care of Me Video
Description: The video's conceptual framework incorporates Social Cognitive Theory, Information-Motivation-Behavioral Skills model, and Social Action Theory, which together address cognitive and behavioral factors related to study outcomes. Storylines embedded prevention messages aimed at increasing treatment initiation (n=9), medication adherence (n=35), retention in care (n=22), partner protection (n=12), and communication with health care providers (n=7).
Study NCT01015404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trafermin
Description: Administered to the bone defect during flap operation
Study NCT00695071 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Itraconazole
Description: Oral
Study NCT01371968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alfentanil
Description: Alfentanil is administered intravenously at the end of surgery.
Study NCT02249988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABX203 therapeutic Hepatitis B vaccine treatment arm
Study NCT03601910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D308 10mg Tab.
Description: D308 10mg Tab.1T single oral administration under fasting condition
Study NCT03601910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-380 10mg Tab.
Description: CKD-380(Dapagliflozin) 10mg Tab.1T single oral administration under fasting condition
Study NCT04777968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silver diamine fluoride
Description: a layer of 38% SDF solution was topically applied to the cavity using a micro brush, immediately followed by a saturated Potassium Iodide KI solution using a micro brush also, then a creamy white precipitate was immediately formed, KI was applied until the white precipitate turned clear.
Study NCT01202955 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tolcapone
Description: Day 1 100mg three times per day Day 2 - Day 7 200mg three times per day Day 8 200mg twice a day Day 9 200mg once a day Day 10 100mg once a day
Study NCT01202955 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Day 1 100mg three times per day Day 2 - Day 7 200mg three times per day Day 8 200mg twice a day Day 9 200mg once a day Day 10 100mg once a day
Study NCT04518748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yttrium-90
Description: Radioactive isotope Y-90 at day 0, administered by selective internal radiation therapy (SIRT)
Study NCT04518748 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Selective Internal Radiation Therapy
Description: SIRT at day 0, to administer Yttrium-90 (Y-90) Theraspheres
Study NCT04518748 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: 3-5 fractions over 1-2 weeks, after Y-90 SIRT
Study NCT04518748 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET/CT
Description: Within 3 hours of completing Y-90 SIRT
Study NCT04146155 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard-of-care treatment
Description: Standard-of-care treatment including: metformin should be given as the first line therapy as long as it is tolerated and not contraindicated; other agents, including sulfonylureas or glucosidase inhibitor or insulin, should be added to metformin .Glycemic control will be managed by the investigators in accordance with local clinical practice guidelines by the adjustment of concomitant glucose-lowering agents or the addition of new antidiabetic medications with the exception of incretin and SGLT2i therapies. This approach expect to yield similar glycemic control in the two study groups.
Study NCT04518748 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Therasphere
Description: Glass microspheres containing Y-90, administered at day 0 by SIRT
Study NCT03614611 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Contiform pessary
Description: Patients will be asked to use the device for 12 weeks and to become comfortable with self-insertion and self-removal. The device can be worn continuously for 1 month. When placed in the vagina it retains its shape and supports the urethra during episodes of varied intraabdominal pressure. During the assessment test (24 hours pad test), patients will be encouraged to undertake any activity that would normally induce stress leakage.~The contiform device is approved by Health Canada since 2017-04-10 (Licence No.: 98950, Company ID: 134089, Device identifier: SKU 184)
Study NCT00158028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone
Description: The dosage of risperidone was titrated upward in a stepwise design, beginning with 0.25 mg/d for the first week, 0.5 mg/d for weeks 2 and 3, 1.0 mg/d for weeks 4 and 5, 1.5 mg/d for weeks 6 and 7, and 2.0 mg/d for the remaining weeks.
Study NCT00158028 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo match in identical tablets
Study NCT03934658 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NightWare Therapeutic System
Description: A wearable digital therapeutic system that will measure physiologic data when worn during sleep to deliver a mild vibration via the watch to elicit arousal thereby disrupting nightmares. This detection and stimulation sequence will be performed according to NightWare's proprietary algorithm.
Study NCT03934658 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: NightWare Therapeutic System in Sham Mode
Description: A wearable digital therapeutic system that will measure physiologic data when worn during sleep that does not deliver interventions.
Study NCT04655131 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Whey protein isolate
Description: Commercially available, FDA approved whey protein isolate for dietary supplementation